Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference
You may also be interested in...
With Singapore’s biomedical infrastructure and small population, it is an ideal place to test devices that could redefine the way therapies are developed and monitored.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).